The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation
|
|
- Lenard Owen
- 8 years ago
- Views:
Transcription
1 The European Clinical Trials Framework Update on the Draft Clinical Trials Regulation Dr. Ilona Reischl BASG/AGES Austrian Agency for Health and Food Safety GmbH
2 Content - References "Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC OPINION on the proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC European Parliament; ITRE Committee - Opinions Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006 (October 2012) EudraLex Vol. 10 2
3 Statistics # of CT applications (e.g. 1 entry for CT in AT, DE, UK) Total # of CT applications (e.g. 3 entries for CT in AT, DE, UK) Total
4 Draft Clinical Trial Regulation The Concepts Harmonised authorisation dossier (EudraLex, Vol. 10) Free, single portal for submission managed by the EC Flexible and swift assessment largely controlled by MS Involvement of all intended Member States Clear timelines - tacit approval Coordination/advisory forum managed and chaired by the Commission Distinction between cooperative and intrinsic ethical or national/local aspects `Qualified opt-out for a MS 4
5 The Concepts Organisational setup and internal competences MS responsibility Swift procedure to extend a CT to additional MSs Modification subject to authorisation only if it has substantial impact on the safety or rights of the subjects or on the reliability and robustness of the data generated in the CT Crucial element: clear distinction between aspects where MSs shall cooperate and those where MSs conduct assessment individually: Aspects which are of an intrinsically national (for example, liability), ethical (for example, informed consent), or local (for example suitability of the clinical trial site) nature 5
6 Clinical Study.. any investigation in relation to humans intended a) to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal products; b) to identify any adverse reactions to one or more medicinal products; or c) to study the absorption, distribution, metabolism and excretion of one or more medicinal products; with the objective of ascertaining their safety or efficacy 6
7 Clinical Trial a clinical study which fulfils any of the following a) the IMPs are not authorised b) IMPs are not used in accordance with the terms of the MA of the Member State concerned c) Therapeutic strategy assignment of the subject is decided in advance and does not fall within normal clinical practice of the Member State concerned d) decision to prescribe the IMP is taken together with the decision to include the subject in the clinical study e) diagnostic or monitoring procedures in addition to normal clinical practice are applied to the subjects 7
8 Low-interventional Clinical Trial.. a clinical trial which fulfils all of the following: a) the IMPs are authorised b) according to the protocol of the clinical trial, the IMPs are used in accordance with the terms of the MA or their use is a standard treatment in any of the Member States concerned c) the additional diagnostic or monitoring procedures do not pose more than minimal additional risk or burden to the safety of the subjects compared to normal clinical practice in any Member State concerned 8
9 Open Question Routine Clinical Practice How should Routine Clinical Practice be documented/supported? When does clinical use become normal clinical practice? The procedure/documentation needs to be harmonized, since it needs to be accepted from any member state How can this be verified in general and in particular during validation? Evidence based medicine Is standard treatment (in any member state) supported by the same level of evidence as a MA? 9
10 Single Authorization The National authorisation of CT should incorporate all aspects One single administrative decision per Member State Decision on appropriate body or bodies is Member State responsibility (NCA, EC), but involvement of lay persons, patients and necessary expertise need to be insured Assessment should be done jointly by a reasonable number of independent persons who collectively have the necessary qualifications and experience The purported elimination of ethics assessment through the CT regulation is an incorrect interpretation of the text However, coming to a single decision within the proposed timelines would require a standing ethics committee Independence? 10
11 Single Portal A single portal to submit an application for conducting a clinical trial linked to an EU database. This portal is managed by the European Commission and is free of charge for sponsors All information is transferred through the portal All communication is transferred through the portal Vital role of a functioning portal otherwise complete standstill! No text on consequences of system failure in the draft regulation No details on how and where information is meant to be archived Implications for IT Systems of Agencies and Industry 11
12 CT Lifecycle In order to allow patients to assess possibilities to participate in a CT, and to allow for effective supervision of a CT by the Member State concerned, the start of the CT the end of recruitment for the CT and the (national) end of the CT should be notified The results of the CT should be reported to the competent authorities within 1 year of the end of the clinical trial Transparency policy 12
13 Assessment Report Part I (i) Anticipated therapeutic and public health benefits (ii) Risks and inconveniences for the subject (iii) Compliance with the requirements concerning the manufacturing and importation of IMPs and auxiliary medicinal products (iv) Compliance with the labelling requirements (v) The completeness and adequateness of the IB 13
14 Assessment Report Part II requirements for informed consent rewards or compensations for investigators and subjects arrangements for recruitment of subjects compliance Dir/95/46/EC (data protection) compliance Art 46 (suitability of personnel) compliance Art 47 (suitability of trial site) compliance Art 72 (damage compensation) compliance with the applicable rules for the collection, storage and future use of biological samples of the subject 14
15 Current VHP Procedure Rapporteur Member states (P-NCAs) Rapporteur NCA Submission Dossier dar Comments AR Assessment Report; GNAs EC Submission Gene technology Act Co-Rapporteur 15
16 Assessment Part I Same procedure for subst. amendments 16
17 Article 14: 2 nd wave Arbitrary example 2 nd wave EU-portal RMS Part II Part II Part II Part I Part II Approval Part II Applicant cms Part II Part II Part II May choose rapporteur Flags from 17
18 Article 11 Limitation to part I Arbitrary example 2 nd wave (Part I)? Followed by 2 nd wave (Part II) Part II Part II EU-portal RMS Part II Part I Part II Applicant Approval Part II Part II Implicit acceptance of Part I assessment Part II Part II Flags from 18
19 Involvement of all intended Member States? The current text does not foresee a draft assessment report Unrealistic timelines Second wave Comments on part I only under very limited conditions and only to the initial rapporteur who decides on relevance? No incentive for multinational trials it seems much easier to go for mononational approval and then a second wave, which, in effect, eliminates the involvement of member states where the trial will be conducted Revisions, restrictions and clarifications needed 19
20 Assessment report AR to be sent to cms, the EC and the applicant previously only deficiencies were sent out Change of policy Higher requirements in preparation time single opinion Publication Benefit? equally for mono-national trials - potential extension to multinational ARs required for substantial modifications Assessment time for multinational CTs is de facto shorter than for mono-national CTs (coordination efforts) 20
21 The same as in the USA? The need for adaptation to the US System is frequently voiced The modus operandi of FDA during the IND stage: Within 30 days the hold/non-hold decision is taken If the study is placed on hold, the (hold-)deficiencies need to be sent out within these 30 days If the study is not placed on hold, a list of (minor) deficiencies may be sent out, but this is not compulsory NO assessment report is sent out According to the EU draft regulation, the entire assessment report needs to be finalized and sent within the timeframe. 21
22 Safety Reporting (Chapter 7) Principles of the applicable international guidance documents streamlined, simplified and modernised: The option to exclude reporting by the investigator to the sponsor of adverse events, if this is provided for in the protocol Direct reporting of SUSARs by the sponsor to EudraVigilance Simplified submission of ASRs by the sponsor for unauthorized IMPs No ASR for authorised IMPs used within their authorised indication 22
23 Withdrawals Withdrawal of the CT by the applicant is possible at multiple stages Art. 12: The sponsor may withdraw the application at any time until the assessment date. In such a case, the application may only be withdrawn with respect to all MS concerned Art. 13:. possibility for the sponsor to submit, following the refusal to grant an authorisation or the withdrawal of an application, an application for authorisation to any intended MS concerned. That application shall be considered as a new application for authorisation of another CT No withdrawal in a single MS possible? 23
24 Withdrawals - Rejections Withdrawal of the CT by the applicant is possible at multiple stages ( Art. 12; Art. 13) but no withdrawal in a single MS foreseen Prediction that significant GNAs cannot be addressed by applicants within the timeframes (10/20d) (preparation of response, internal sign-off) increase in withdrawals/rejections Consequences of rejection and a withdrawal are the same: New EudraCT New Fee 24
25 Summary Based on the initial draft.. Administrative obligations are shifted from applicant to competent authority (coordination of opinions) Same procedure for mono-national and multinational trials EU portal as an essential element of the process Need to establish IT Systems compatible with the portal Timelines are maintained or shortened for agencies in spite of a significant increase in administrative load Double impact on the time available for scientific assessment: Shortened timelines and additional coordinative tasks reflection of the value placed on agency review? 25
26 Comments by the EU Parliament %2B01%2BDOC%2BPDF%2BV0//EN 26
27 Proposed Amendments EU Parliament Explicit mention of evaluation by independent ethics committees Off-label use Focus on transparency Focus on participant s benefit Possible sanctions for non-compliance 27
28 Proposed Amendments EU Parliament In order to allow for independent control as to whether these principles are adhered to, a CTs should be subject to prior authorisation and prior approval by an ethics committee EUP: Currently, the ethics review procedure varies greatly between MS, often with various bodies at national, regional and local levels, and multiple procedures leading to divergent assessments. This is a source of delays and fragmentation. In the interests of European patients and public health, the procedures and principles of ethical review should be better harmonised through the sharing of best practices between ethics committees. To this end the Commission should facilitate the cooperation of ethics committees. Single opinion proposed is not accepted? Duty to get Agency and EC approval falls back to sponsor? Intended procedure unclear 28
29 Off-Label Use Art.2 2 2b: according to the protocol of the clinical study, the investigational medicinal products are not used in accordance with the terms of the marketing authorisation of the Member State concerned and their use does not fall within normal clinical practice; EUP: As many standard treatment protocols use medicines outside their MA, it has to be clarified that studies collecting data on the standard off-label use of a medicinal product are not considered as clinical trials. Impact on evidence based medicine? Data will not be usable for a MAA; impact on paediatric off-label use? 29
30 Off-Label Use Art.2 2 3b: according to the protocol of the CT, the IMPs are used in accordance with the terms of the MA in any of the MS concerned or, where the use of a medicinal product is outside the terms of the MA, their use is supported by sufficient published evidence and/or standard treatment guidelines EUP:. In order to avoid fundamental differences between MS in applying the definition of a low-interventional trial including off-label use, the acceptable level of evidence should be stated; and if the trial treatment is only to compare standard practice treatment approaches, then, regardless of whether the drugs are being used off-label, the trial should be categorised within the lowinterventional trial category. Considers only risk of therapeutic but not diagnostic intervention 30
31 Study Report Art. 2, 2 30 a (new) Clinical study report : a report containing the full protocol and any subsequent modifications and dates thereof, a statistical analysis plan, summarised efficacy and safety data on all outcomes, and individual anonymised patient data in the form of tabulations or listings, in accordance with the guidelines provided by the ICH E3. Same requirements for all CTs Art. 3 2: EUP: CTs should be conducted only if the results are relevant for improving the prevention and treatment of diseases. The relevance of the trial is one of the assessment criteria pursuant to Art. 6, and should therefore be included in the general principles of CTs. 31
32 Population to be treated Art. 6 1 a) i ) 2 the relevance of the CT, ensuring that the groups of subjects participating in the trials represent the population to be treated, and taking account of the current state of scientific knowledge, and of whether the CT has been recommended or imposed by regulatory authorities in charge of the assessment and authorisation of the placing on the market of medicinal products Art. 31 a (f) some direct benefit for the group of patients (e.g. improved quality of life) is obtained from the CT. Annex I, 13, 6 if the trial subjects do not reflect a balanced distribution in age and/or justification for these exclusion criteria; gender, this must be justified and explained; Impact? 32
33 Data robustness Art. 6, 1 a) i) 3: the reliability and robustness of the data generated in the clinical trial, taking account of statistical approaches, design of the trial and methodology (including sample size allowing for a stratified analysis by age and gender and randomisation, comparator and endpoints EUP: The data generated in CTs can be considered as reliable and robust only if they adequately reflect the population groups (e.g. women, the elderly) that are likely to use the product under investigation. Impact on the number of subjects needed for the trials? Early trials? 33
34 Information Art. 29, 4 The subject shall be provided with information on the results of the CT that he or she has participated in, once it has come to an end. Extra information needed? Report will be in the public database Art 34 3: Within one year from the end of a CT, the sponsor shall submit to the EU database the clinical study report, including a lay summary of the CT 34
35 Compliance 2a. In the event of sponsor noncompliance with the obligation referred to in paragraph 3, financial penalties shall be imposed by the Member States concerned. EUP: To ensure compliance with the provision to submit the summary of the results and the CT report within 12 months, the MS should be entitled to enforce a penalty. Art 55: The sponsor and the investigator shall archive the content of the clinical trial master file for an indefinite period of time after concluding the clinical trial. 35
36 Impact Art The EU database..to enable the co-operation between the competent authorities of the MSs..and to search for specific CTs. It shall also enable sponsors to refer to previous submissions of an application for authorisation of a CT or a substantial modification. It shall also enable the public and independent researchers to analyse the results of CTs. Annex I 13 2 Application..a discussion of the relevance of the clinical trial and its design to allow assessment in accordance with Article 6, referencing all existing evidence, including systematic reviews and meta-analysis; 16a. The protocol shall contain information regarding funding, sponsors, institutional affiliations, and any other potential conflicts of interest Consequence on size of the dossiers and assessment? 36
37 Transparency Initiative 2 Levels: EMA: Publication of clinical trial (raw) data once a marketing authorization approval has been given for a specific product Applies only to products after licensure Clinical Trials: Public access to final reports of clinical trials Applies to ALL clinical trials 37
38 EudraLex Volume 10 Guidance on posting and publication of result-related information on clinical trials in relation to the implementation of Article 57(2) of Regulation (EC) No 726/2004 and Article 41(2) of Regulation (EC) No 1901/2006 (October 2012) Applicability as soon as IT programming finalized Result-related information should be posted for all clinical trials, including those prematurely ended Reporting by the sponsor of the trial, the addressee of a PIP decision or the MA holder (Art 45/46 REG/1901/2006/EC) Upload via secure account, publication after techn. validation No review by National Agencies prior to publication Publication via the EU Clinical Trials Register 38
39 EudraLex Volume 10 Automatic upload of required protocol-related information from EudraCT, to be included with result-related information Upload required within 6 months (paediatric trials) or 1 year Member States should verify upload for CTs authorized by them Non-compliance publicly flagged within 9/15 months Applies retrospectively: ο ο Trials that ended less than 1 year prior to IT availability - 1 year for upload Trials that ended 1 year or more prior to availability - 24 months based on full data, with exception of trials according to Art. 45 REG/1901/2006/EC IT structure published Considerable impact on sponsors 39
40 Public Initiatives 40
41 Thank you for your attention! 41
Clinical trials regulation
Clinical trials regulation The Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use and Repealing Directive 2001/20/EC an update
More informationClinical research: where are we with the new (Paediatric) RC trial Regulation
where are we with the new (Paediatric) RC trial Regulation, MD, PhD Ethical Committee DEEP Former member of the PDCO EMA With the aid of Fabio D'Atri European commission and Anabela Marcal of EMA The new
More informationFederal agency for medicines and health products
Federal agency for medicines and health products A critical review of the proposed EU Clinical Trial regulation Walter Janssens Kristof Bonnarens April 2013 CT regulation - general Commission adopted the
More informationWhite Paper The EU Clinical Trials Regulation Main Changes and Challenges
White Paper The EU Clinical Trials Regulation Main Changes and Challenges Table of Contents 1. Introduction... 3 2. Main Changes and Associated Challenges... 4 2.1 Procedure for Initial Authorisation...
More informationResponse of the German Medical Association
Response of the German Medical Association to the European Commission proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and
More informationThe EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationThe New EU Clinical Trials Regulation: The Good, the Bad, the Ugly
A Full-Service International CRO The New EU Clinical Trials Regulation: The Good, the Bad, the Ugly Dr. Martine Dehlinger-Kremer Vice President, Global Medical and Regulatory Affairs The original intent
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationThis is meant to be a narrative rather than a critical summary I have a lot of questions about the proposal but I will look into these separately.
REVISION OF THE CLINICAL TRIALS DIRECTIVE Proposal for a Regulation of the European Parliament and of the Council on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC.
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationProposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Brussels, 17.7.2012 COM(2012) 369 final 2012/0192 (COD) Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on clinical trials on medicinal products for human use,
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationClinical Trials Facilitation Groups
Clinical Trials Facilitation Groups Guidance document for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications Version 2 Table of contents Doc. Ref.:
More informationThe EU portal and database
The EU portal and database ECPC General Assembly - 20 June 2015 Presented by Laura Pioppo Clinical and Non-clinical Compliance Service An agency of the European Union Table of contents Legal basis CT programme
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationClinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation
Clinical Trial Data Transparency Environment & Expectations EMA Policy - Clinical Trials Regulation Joint BBS-EFSPI Seminar, Basel, 13 Nov 2014 Sabine Atzor, Head of EU Regulatory Policies PDR Overview
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT
More informationThe new European clinical trials regulation Dr. N.Gökbuget
The new European clinical trials regulation Dr. N.Gökbuget Head of Study Center Department of Medicine II and Goethe University Cancer Center Frankfurt, Germany European Leukemia Net: Major Aim to Foster
More informationOfficial Journal of the European Union. (Acts whose publication is obligatory)
27.12.2006 L 378/1 I (Acts whose publication is obligatory) REGULATION (EC) No 1901/2006 OF THE EUROPEAN PARLIAMT AND OF THE COUNCIL of 12 December 2006 on medicinal products for paediatric use and amending
More informationHaving regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to
More informationStrong support. Remaining concerns
EORTC opinion on the proposal for an EU Regulation on clinical trials on medicinal products for human use and the 7 th of June ENVI report on this proposal It is clear that the Commission and appointed
More informationOverview of the EU CTA Regulatory Framework and Future Direction of the EU Clinical Trial Directive. Features
72 Features STEPHAN REYNIER Project Director Voisin Consulting, France Overview of the EU CTA Regulatory Framework and Future Direction of the EU Clinical Trial Directive Over the last few years, the European
More informationQuestions and Answers to the Annual Safety Report
Questions and Answers to the Annual Safety Report Frequently asked questions regarding the Development Safety Update Report (DSUR) Question 1 DSUR Start Stop 1.1 When to start preparing and where to submit
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationEarly Phase Clinical Trials: Public Access to the EU Database Repository
European CRO Federation Via Lucrezio Caro, 63 00193 Roma, Italy Tel.: +39 06 807 60 72 Fax: +39 06 807 60 85 Email: info@eucrof.eu Internet: www.eucrof.eu Early Phase Clinical Trials: Public Access to
More informationEORTC position on the place for transparency in the clinical trials regulation
EORTC position on the place for transparency in the clinical trials regulation EORTC fully supports the need to increase transparency of clinical trials. Appropriate transparency within the clinical trials
More informationGuide to Clinical Trial Applications
Guide to Clinical Trial Applications AUT-G0001-9 DATE 29 JUNE 2015 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationRegulatory approval routes in the European System for Medicinal Products
Regulatory approval routes in the European System for Medicinal Products Cardiovascular Combination Pharmacotherapy Global Summit, Melbourne, 8 th May 2014 Presented by: Kevin Blake Human Medicines Research
More information20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationRegulation of clinical trials with medicinal products: Where are we now?
Regulation of clinical trials with medicinal products: Where are we now? Mariantonia Serrano Castro Department of Medicines for Human Use Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
More informationLegal and governance framework
Annex A Legal and governance framework This annex is a brief guide to the legal and governance framework relevant to research in the UK. It is not intended to be a comprehensive statement of the law or
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON DATA MONITORING COMMITTEES
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 July 2005 Doc. Ref. EMEA/CHMP/EWP/5872/03 Corr COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More information2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials
L1 2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager,
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationHow To Understand The Paediatric Regulation
Paediatric Use Marketing Authorisation (PUMA) from a National Competent Authority Point of View DGRA Annual Congress 2006 Bonn, 10. May 2006 Dr. Susanne Keitel Content PUMA The Future Background Legislative
More informationOECD Recommendation on the Governance of Clinical Trials
OECD Recommendation on the Governance of Clinical Trials Marketing authorisation status of the medicinal products Non-authorised medicine Authorised medicine, treatment regimen outside
More informationWORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects
WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationGUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES
Foreword GUIDANCE NOTES FOR MANUFACTURERS OF CLASS I MEDICAL DEVICES These guidance notes do not aim to be a definite interpretation of National Laws and/or regulations and are for guidance purpose only.
More informationStandard Operating Procedure. Clinical Trial Authorisation
Standard Operating Procedure for Clinical Trial Authorization Scope This SOP has been written to describe the procedure undertaken to apply for Clinical Trial Authorisation from Competent Authorities in
More informationGuidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Guidance on Investigational Medicinal Products (IMPs) and other medicinal products used in Clinical Trials
More informationA 4.5 Validity Period of a Marketing Authorisation
104 A 4.5 Examples of situations in which the notification procedure according to Art. 61(3) of the Community Code will apply are as follows: Minor changes to the package leaflet resulting from readability
More informationEU Clinical Trials Register
EU Clinical Trials Register Disclaimer: The explanations are provided for the benefit of public users of the system and to enhance general understanding of terms used. They are not intended as the regulatory
More informationTemplate for essential information to be provided for proposals including clinical trials / studies / investigations
Template for essential information to be provided for proposals including clinical trials / studies / investigations Document history Version 2016callsV1 September 2015 Modifications (compared to previous
More informationQuestions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
More informationDefinition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products (NIMPs)
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Definition of Investigational Medicinal Products (IMPs) Definition of Non Investigational Medicinal Products
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationGuideline on good pharmacovigilance practices (GVP)
19 April 2013 EMA/813938/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VIII Post-authorisation safety studies (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationDESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004
DESCRIPTION OF THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Page 1 of 17 TABLE OF CONTENTS INTRODUCTION 4 EXECUTIVE SUMMARY 4 PUBLIC HEALTH BENEFITS 5 Good clinical practice 5 Good manufacturing
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Denmark Question 1: What laws or regulations apply to an application for conducting a clinical
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationWhat is necessary to provide good clinical data for a clinical trial?
What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationGOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE
ICH E6 GCP: Consolidated Guideline: Investigator 1/7 Institutional Review Board Services ICH HARMONIZED TRIPARTITE GUIDELINE E6: GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE 4. INVESTIGATOR 4.1 Investigator's
More informationEFPIA position on Clinical Trials Regulation trialogue
EFPIA position on Clinical Trials Regulation trialogue As the revision of the Clinical Trial Directive enters the Trialogue phase, it is critical to remember that the key objective of this legislation
More informationMedicines for Human Use (Clinical Trials Regulations) 2004. Informed consent in clinical trials
Medicines for Human Use (Clinical Trials Regulations) 2004 Informed consent in clinical trials Introduction 1. This information note summarises the statutory requirements for informed consent of participants
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL. Brussels, ENTR/F2/BL D(2003) CT 1 Revision 2
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Brussels, ENTR/F2/BL D(2003)
More informationAct of 26 February 1998, containing rules on medical research involving human subjects (Medical Research (Human Subjects) Act)
[This is an unofficial translation and is provided for reference purposes only. It is not certified and it has not been authorised by the Dutch government; persons using this translation do so entirely
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health products and systems Medicinal products quality, safety and efficacy Brussels, 15 May 2013 sanco.ddg1.d.6(2013)1154216 THE RULES GOVERNING
More informationSheffield Kidney Institute. Planning a Clinical Trial
Planning a Clinical Trial Clinical Trials Testing a new drug Ethical Issues Liability and Indemnity Trial Design Trial Protocol Statistical analysis Clinical Trials Phase I: Phase II: Phase III: Phase
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationEuropean Regulatory Newsletter July - September 2013
European Regulatory Newsletter July - September 2013 Introduction CROMSOURCE is committed to sharing our expertise with our clients and future clients. This reflects the first part of our Advise Agree
More informationSubmission of comments on 'Policy 0070 on publication and access to clinical-trial data'
EMA/240810/2013 Submission of comments on 'Policy 0070 on publication and access to clinical-trial data' s from: Name and affiliation For the Austrian Medicines & Medical Devices Agency (AGES), Austria,
More informationEnd of consultation (deadline for comments) 14 October 2009. Adoption by Committee for advanced therapies 15 October 2010
15 October 2010 EMA/CAT/418458/2008/corr. Committee for advanced therapies (CAT) Procedural advice on the certification of quality and nonclinical data for small and medium sized enterprises developing
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationStudy Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
More informationCESR Consultation Paper on UCITS Management Company Passport
News Bulletin October 24, 2008 CESR Consultation Paper on UCITS Management Company Passport Background On 30 th September 2008, the Committee of European Securities Regulators ( CESR ) issued a consultation
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)
European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Sweden
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe Sweden Question 1: What laws or regulations apply to an application for conducting a clinical trial in Sweden?
More informationROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
More informationClinical trials in developing countries submitted to EMEA for regulatory purposes
Clinical trials in developing countries submitted to EMEA for regulatory purposes Rome, UNICRI/AIFA December 2008 Hans-Georg Eichler Agenda Challenges EU regulatory requirements for clinical trials Facts
More informationMedical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules?
Medical Device Directive 2007/47/EC What is New? Are we moving towards Drug Rules? CEMO Congress, Paris, February 3rd, 2011 Dr. Martine Dehlinger-Kremer Vice President Global Regulatory Affairs Agenda
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationKey considerations for outsourcing late phase clinical research
Key considerations for outsourcing late phase clinical research Alan Nelson (on behalf of Van Zyl Engelbrecht) Senior Project Director at UBC: An Express Script Company Layout of presentation My presentation
More informationREGULATION (EEC) No 2309/93
REGULATION (EEC) No 2309/93 Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use
More informationGUIDELINES ON MEDICAL DEVICES EVALUATION OF CLINICAL DATA : A GUIDE FOR MANUFACTURERS AND NOTIFIED BODIES
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single Market : regulatory environment, standardisation and New Approach Pressure equipment, medical devices, metrology MEDDEV. 2.7.1 April 2003 GUIDELINES
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL
More informationBIO-PARTNERING EUROPE EVENT SPEECH PAOLA TESTORI COGGI DIRECTOR GENERAL FOR HEALTH AND CONSUMERS EUROPEAN COMMISSION
EUROPABIO BIO-PARTNERING EUROPE EVENT TUESDAY 9 OCTOBER 2012 9.10 9.20 HRS SPEECH BY PAOLA TESTORI COGGI DIRECTOR GENERAL FOR HEALTH AND CONSUMERS EUROPEAN COMMISSION I am pleased to have the opportunity
More informationEudraVigilance stakeholder change management plan
26 October 2015 EMA/797114/2014 Information Management Division Consultation of Project Maintenance Group 1 15 July 2015 Consultation of Eudravigilance Expert Working Group 23 September 2015 Consultation
More informationLEBANESE MINISTRY OF HEALTH DIRECTIVE
LEBANESE MINISTRY OF HEALTH DIRECTIVE LAYING DOWN DETAILED GUIDELINES FOR SPONSORS OF CLINICAL TRIALS March 2012 Field of Application General Considerations Trial s submission Validity of the F-MRI opinion
More informationEthical Considerations for Clinical Trials performed in Children
Ethical Considerations for Clinical Trials performed in Children Dr. Michael Berntgen DAKJ-Workshop Berlin, 01.12.2006 Regulatory framework specifically addressing paediatric medicines Guideline ICH E11
More informationSETTING UP INTERNATIONAL CLINICAL TRIALS IN EUROPE: THE EORTC EXPERIENCE
SETTING UP INTERNATIONAL CLINICAL TRIALS IN EUROPE: THE EORTC EXPERIENCE Dr. Pharm. Fabienne LAMBERT, PhD Head Regulatory Affairs Unit European Organisation for Research and Treatment of Cancer (EORTC)
More informationVOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. November 2005
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, ENTR/F2/BL D(2002) NOTICE TO APPLICANTS Revision 3 VOLUME 2A Procedures for marketing authorisation CHAPTER 1
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 July 2006 Doc. Ref. EMEA/419127/05 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PROCEDURE
More informationPost-authorisation safety studies and the EU PAS Register
Post-authorisation safety studies and the EU PAS Register Xavier Kurz European Medicines Agency EMA, 11 October 2012 An agency of the European Union Content of the presentation 1. PASS: definition and
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationOvercoming cancer with research Vienna 15 th -17 th May, 2008. Session 3: Established therapeutic compounds
Overcoming cancer with research Vienna 15 th -17 th May, 2008 Session 3: Established therapeutic compounds Introduction Randomized clinical trials: bedrock of progress in children with cancer in the last
More informationTHE CLINICAL TRIALS BILL (No. XIX of 2010) Explanatory Memorandum
THE CLINICAL TRIALS BILL (No. XIX of 2010) Explanatory Memorandum 1. The object of this Bill is to provide the legal framework for the conduct of clinical trials for the purpose of discovering or verifying
More informationHow to search the EU Clinical Trials Register
28 April 2014 Information and Communications Technology Contents Contents... 1 1. Searching the EU Clinical Trials Register... 1 1.1. Basic search... 2 1.2. Search for multiple words (AND operator)...
More informationArchiving of Clinical Trial Data and Essential Documentation JCTO/CT/SOP 4.0. Joint Clinical Trials Office. Stuart Hatcher, JCTO Archivist
Archiving of Clinical Trial Data and Essential Documentation Policy Details Document Type Standard Operating Procedure Document name Change History Date Version Number JCTO/CT/SOP 4.0 Version Final v 2.0-09/11/2010
More informationBackground Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
Joanna Forbes Senior Clinical Research Nurse Ethical and legal considerations Background Definition Why do we need it? The process of obtaining informed consent A brief overview of special situations Conclusion
More informationHow To Know If A Mobile App Is A Medical Device
The Regulation of Medical Device Apps Prepared for West of England Academic Health Science Network and University of Bristol June 2014 June 2014 1 Table of Contents 1 Purpose...3 2 Scope...3 3 The Regulation
More information